Abstract
Purpose
Recently, mutations in the epidermal growth factor receptor (EGFR) gene were reported to correlate with EGFR tyrosine kinase inhibitor response in advanced non-small cell lung cancer (NSCLC). In this study, we attempted to detect EGFR mutations in plasma and pleural effusion samples and to make clear its correlations with gefitinib response and survival in NSCLC patients.
Methods
The free DNA was isolated from the plasma of 56 cases and pleural effusion of another 32 cases of advanced NSCLC. Five common types of EGFR mutations were analyzed by LightCycle PCR with Taqman-MGB probes.
Results
EGFR gene mutations were found in 22 of all the 88 (25%) NSCLC patients (23.2% of 56 plasma samples, 28.1% of another 32 pleural effusion samples). EGFR mutations were more frequently present in females, never-smokers and adenocarcinomas (P < 0.01). It also showed that patients with EGFR mutations had a significantly better response rate when compared with that of the wild-type patients (P < 0.001). The median progression-free survival (11.2 vs. 2.7 months P = 0.005) and overall survival (21.8 vs. 5.8 months P = 0.003) were significantly higher in patients with EGFR mutations than in patients with wild-type EGFR.
Conclusions
The EGFR mutations in the serum and the pleural effusion from advanced NSCLC patients can be detected with LightCycle PCR using Taqman-MGB probes. The mutations highly predict the efficacy of gefitinib in advanced NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M et al (1995) Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4:249–255. doi:10.1097/00019606-199512000-00004
Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742
Dong Q, Huang J, Zhou Y, Li L, Bao G, Feng J et al (2002) Hematogenous dissemination of lung cancer cells during surgery; quantitative detection by flow cytometry and prognostic significance. Lung Cancer 37:293–301. doi:10.1016/S0169-5002(02)00102-2
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small-cell lung cancer patients. Cancer Res 59:67–70
Fan X, Furnari FB, Cavenee WK, Castresana JS (2001) Non-isotopic silverstained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Oncol 18:1023–1026
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246. doi:10.1200/JCO.2003.10.038
Han SW et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493–2501. doi:10.1200/JCO.2005.01.388
Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K et al (2006a) EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95:1390–1395. doi:10.1038/sj.bjc.6603428
Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B et al (2006b) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921. doi:10.1158/1078-0432.CCR-05-2324
Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S et al (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778–784. doi:10.1038/sj.bjc.6603949
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792. doi:10.1056/NEJMoa044238
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923. doi:10.1158/0008-5472.CAN-04-2818
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158. doi:10.1001/jama.290.16.2149
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665–7670. doi:10.1073/pnas.0502860102
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139. doi:10.1056/NEJMoa040938
Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865. doi:10.1200/JCO.2005.08.043
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520. doi:10.1200/JCO.2005.00.992
Moran T, Paz-Ares L, Isla D et al. (2007) High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients with poor performance status. In: ASCO annual meeting proceedings Part I, vol 25, No.18S, pp 7505
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500. doi:10.1126/science.1099314
Pals G, Pindolia K, Worsham MJ (1999) A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn 4:241–246. doi:10.1016/S1084-8592(99)80027-7
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(13):306–311
Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543
Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl):2379–2385
Sánchez-Céspedes M, Monzó M, Rosell R, Pifarré A, Calvo R, López-Cabrerizo MP et al (1998) Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:113–116. doi:10.1023/A:1008230331221
Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K et al (2005) EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11:2924–2929. doi:10.1158/1078-0432.CCR-04-1904
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
Sonobe M, Tanaka F, Wada H (2004) Lung cancer—related genes in the blood. Ann Thorac Cardiovasc Surg 10:2l3–2l217
Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205
Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22:130–138
Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ (2007) Detection of epidermal growth factor receptor mutations in non-small-cell lung cancer by rea1-time PCR using TaqMan-MGB probes. Chin J Oncol 29:119–123
Acknowledgments
This work was supported by a grant from Science and Technology Commission of Shanghai Municipality (No. 06DZ19502)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jian, G., Songwen, Z., Ling, Z. et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 136, 1341–1347 (2010). https://doi.org/10.1007/s00432-010-0785-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0785-z